NST has collaborated with Erytech Pharma SA for several years. Erytech Pharma SA approached NST as it needed the very best partner to understand the challenges ahead and be pro-active in finding the necessary solutions. The NST team quickly integrated with the Erytech Pharma SA team, enabling efficient and successful delivery of projects.

The company was challenged with needing to re-visit previously written clinical study reports from historical studies. The existing CSRs were either synoptic or of a very poor quality, far below the requirement for their planned BLA submission. The NST installed its own delivery mechanisms in terms of its document templates, writing processes and guides, all working under the Erytech Pharma SA quality system. This served to accelerate project delivery.

NST subsequently worked with Erytech Pharma SA on several related regulatory projects. This included re-writing clinical study reports for their pivotal eryaspase trials in various oncological indications.  NST’s involvement went beyond merely writing capability – it involved understanding the bigger picture. Collectively, the NST team had the experience necessary to envisage the clinical implications of the reported observations when writing and reviewing the study narratives. This experienced proved invaluable in navigating the regulatory pathway.